Results from a first-in-human study (PROCLAIM-CX-2029) in patients (Pts) with advanced cancer – Melissa Lynne Johnson MD – Sarah Cannon Research Institute @SarahCannonPR #advancedcancer

Melissa Johnson, MD, Associate Director, Lung Cancer Research and Drug Development, Sarah Cannon Research Institute at Tennessee Oncology discusses CX-2029, a PROBODY drug conjugate targeting CD71 (transferrin receptor): Results from a first-in-human study (PROCLAIM-CX-2029) in patients (Pts) with advanced cancer. 

ASCO

https://meetinglibrary.asco.org/record/185085/abstract